Results 231 to 240 of about 36,119 (263)
Some of the next articles are maybe not open access.
Current Osteoporosis Reports, 2019
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple ...
Olivier, Lamy +3 more
openaire +2 more sources
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple ...
Olivier, Lamy +3 more
openaire +2 more sources
Bone & Joint 360, 2013
It is not often that a new drug becomes available that is likely to affect the workload of orthopaedic surgeons, but denosumab has that potential. This edition of 360 carries a summary of a potentially landmark RCT examining the use of denosumab in giant cell tumour of bone. Denosumab is a fully human monoclonal antibody that inhibits RANK-L (Receptor
+5 more sources
It is not often that a new drug becomes available that is likely to affect the workload of orthopaedic surgeons, but denosumab has that potential. This edition of 360 carries a summary of a potentially landmark RCT examining the use of denosumab in giant cell tumour of bone. Denosumab is a fully human monoclonal antibody that inhibits RANK-L (Receptor
+5 more sources
Current Opinion in Rheumatology, 2009
Denosumab is an investigational fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand, an essential mediator of osteoclastic bone resorption. Receptor activator of nuclear factor kappaB ligand plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheumatoid arthritis, and bone loss ...
openaire +2 more sources
Denosumab is an investigational fully human monoclonal antibody to receptor activator of nuclear factor kappaB ligand, an essential mediator of osteoclastic bone resorption. Receptor activator of nuclear factor kappaB ligand plays a major role in the pathogenesis of postmenopausal osteoporosis, structural damage in rheumatoid arthritis, and bone loss ...
openaire +2 more sources